|
1
|
Crawford J, Caserta C and Roila F: ESMO
Guidelines Working Group: Hematopoietic growth factors: ESMO
Clinical Practice Guidelines for the applications. Ann Oncol. 21
Suppl 5:v248–v251. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dale DC: Colony-stimulating factors for
the management of neutropenia in cancer patients. Drugs. 62 Suppl
1:1–15. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Naurois J, Novitzky-Basso I, Gill MJ,
Marti FM, Cullen MH and Roila F: ESMO Guidelines Working Group:
Management of febrile neutropenia: ESMO Clinical Practice
Guidelines. Ann Oncol. 21 Suppl 5:v252–v256. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
European Commission, . Community register
of medicinal products for human use: Accofil. http://ec.europa.eu/health/documents/community-register/html/h946.htmFeb
11–2017
|
|
5
|
Greil R, Psenak O and Roila F: ESMO
Guidelines Working Group: Hematopoietic growth factors: ESMO
recommendations for the applications. Ann Oncol. 19 Suppl
2:ii116–ii118. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Aapro MS, Bohlius J, Cameron DA, Dal Lago
L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC,
Walewski J, et al: European Organisation for Research and Treatment
of Cancer: 2010 update of EORTC guidelines for the use of
granulocyte-colony stimulating factor to reduce the incidence of
chemotherapy-induced febrile neutropenia in adult patients with
lymphoproliferative disorders and solid tumours. Eur J Cancer.
47:8–32. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Weise M, Bielsky MC, de Smet K, Ehmann F,
Ekman N, Narayanan G, Heim HK, Heinonen E, Ho K, Thorpe R, et al:
Biosimilars-why terminology matters. Nat Biotechnol. 29:690–693.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dranitsaris G, Amir E and Dorward K:
Biosimilars of biological drug therapies: Regulatory, clinical and
commercial considerations. Drugs. 71:1527–1536. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gottlieb S: Biosimilars: Policy, clinical,
and regulatory considerations. Am J Health Syst Pharm. 65 Suppl
6:S2–S8. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kuderer NM, Dale DC, Crawford J and Lyman
GH: Impact of primary prophylaxis with granulocyte
colony-stimulating factor on febrile neutropenia and mortality in
adult cancer patients receiving chemotherapy: A systematic review.
J Clin Oncol. 25:3158–3167. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Blackwell K, Semiglazov V, Krasnozhon D,
Davidenko I, Nelyubina L, Nakov R, Stiegler G, Singh P, Schwebig A,
Kramer S, et al: Comparison of EP2006, a filgrastim biosimilar, to
the reference: A phase III, randomized, double-blind clinical study
in the prevention of severe neutropenia in patients with breast
cancer receiving myelosuppressive chemotherapy. Ann Oncol.
26:1948–1953. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tesch H, Ulshöfer T, Vehling-Kaiser U,
Ottillinger B, Bulenda D and Turner M: Prevention and treatment of
chemotherapy-induced neutropenia with the biosimilar filgrastim: A
non-interventional observational study of clinical practice
patterns. Oncol Res Treat. 38:146–152. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Erratum G, ascón P, Aapro M, Ludwig H,
Bokemeyer C, Boccadoro M, Turner M, Denhaerynck K, MacDonald K and
Abraham I: Treatment patterns and outcomes in the prophylaxis of
chemotherapy-induced (febrile) neutropenia with biosimilar
filgrastim (the MONITOR-GCSF study). Support Care Cancer.
24:911–925. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nahon S, Rastkhah M, Ben Abdelghani M,
Soumoudronga RF, Gasnereau I and Labourey JL: Zarzio®, biosimilar
of filgrastim, in prophylaxis of chemotherapy-induced neutropenia
in routine practice: A French prospective multicentric study.
Support Care Cancer. 24:1991–1998. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bongiovanni A, Monti M, Foca F, Recine F,
Riva N, Di Iorio V, Liverani C, de Vita A, Miserocchi G, Mercatali
L, et al: Recombinant granulocyte colony-stimulating factor
(rG-CSF) in the management of neutropenia induced by anthracyclines
and ifosfamide in patients with soft tissue sarcomas (NEUSAR).
Support Care Cancer. 25:111–117. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Verpoort K and Möhler TM: A
non-interventional study of biosimilar granulocyte
colony-stimulating factor as prophylaxis for chemotherapy-induced
neutropenia in a community oncology centre. Ther Adv Med Oncol.
4:289–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
